Can Weight Loss Drugs Curb Alcoholism? See What Study Says

Updated Feb 13, 2025 | 09:02 AM IST

SummaryResearchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.
Can weightloss drug curb alcoholism?

Credits: Canva

Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

End of Article

112 Pregnant Women, 13 Newborns Infected With Measles In US Since 2025: CDC

Updated Nov 18, 2026 | 02:00 AM IST

SummarySummary: A CDC-led report identified 112 measles infections among pregnant women and 13 cases of congenital measles in newborns in the US between January 2025 and September 2026. Nearly all infected women were unvaccinated or had an unknown vaccination status, highlighting the risks of declining immunization amid ongoing outbreaks.
112 Pregnant Women, 13 Newborns Infected With Measles In US Since 2025: CDC

Credit: AI Image

The US has lost its measles elimination status after 26 years, with Bolivia and Mexico also losing the designation, the Pan American Health Organization (PAHO) announced on Tuesday. The decision follows more than 12 months of continuous measles transmission in the US.

Amid the resurgence, a CDC-led report has identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns. Nearly all the women were unvaccinated or had an unknown vaccination status.

The actual number of infections among pregnant women may be higher. A separate CIDRAP News investigation based on state health department data identified at least 167 pregnant women infected in 2025 and 2026.

Measles In Unvaccinated Women

Also Read: What Happens After Measles Infection? The Hidden Risks That Can Last For Years

The CDC-led report, published in NEJM Evidence journal, found that 108 (96%) of the 112 cases occurred during outbreaks involving 50 or more cases.

Of the infected women, 110 (98%) had received no MMR vaccine doses or had an unknown vaccination status.

Twenty-six women (23%) were hospitalized for reasons unrelated to childbirth, while 11 (10%) developed pneumonia.

“Even though measles is an old disease, measles in pregnancy is an emerging area that we need to learn about,” said Michelle Barton, a professor at the Schulich School of Medicine & Dentistry at Western University.

Measles In Newborns

Read More: Congenital Measles Reported In Pennsylvania For First Time In Decades: What Parents Should Know

The report recorded 21 pregnancy outcomes within 14 days of maternal rash onset: 19 live births and two pregnancy losses, including one miscarriage and one stillbirth.

Eight babies were born prematurely, and eight required admission to a neonatal intensive care unit (NICU).

The report noted that 13 babies had congenital measles and tested positive for the virus. Of these, six developed symptoms, including one with signs compatible with meningoencephalitis, a potentially life-threatening inflammation of the brain and surrounding membranes.

The authors said the outbreaks highlighted measles' risks to maternal and newborn health.

Many doctors and nurses treating these patients have never encountered measles, relying largely on medical training and professional guidelines to manage the infections.

The CDC recommends intravenous immunoglobulin as post-exposure prophylaxis for pregnant women without documented MMR vaccination or other evidence of immunity who are exposed to measles.

Newborns exposed to measles in the womb should also receive immunoglobulin at birth. Congenital measles can cause severe neurological complications, including subacute sclerosing panencephalitis (SSPE), a rare, progressive brain disorder.

US Loses Measles Elimination Status After 26 Years

The US is experiencing its highest measles burden in more than three decades. Since 2025, approximately 7,700 people have been infected and 13 have died, according to the figures cited in the report.

As of November 12, the CDC had confirmed 5,412 cases and six deaths in 2026. States had reported 10 deaths.

The rise in infections has coincided with declining vaccination rates and growing vaccine hesitancy. US Health Secretary Robert F. Kennedy Jr. has repeatedly questioned measles vaccine safety without scientific evidence supporting those claims.

The CDC said it would work to stop outbreaks and regain elimination status by supporting states and providing sustained national leadership.

"The measles elimination designation is not what protects Americans; vaccination does," CDC Director Erica Schwartz said.

End of Article

Childhood Obesity: Wegovy Cuts BMI By 10% In Children As Young As 6; What Are The Risks?

Updated Nov 17, 2026 | 11:30 PM IST

SummaryNovo Nordisk led trial found that Wegovy reduced BMI by at least 10% in nearly 80% of children aged 6 to under 12 with obesity. However, limited long-term safety data and concerns about appetite suppression, nutritional intake and childhood development raise questions about the use of semaglutide in younger children.
Childhood Obesity: Wegovy Cuts BMI By 10% In Children As Young As 6; What Are The Risks?

Credit: AI Image

A new trial by Novo Nordisk found that Wegovy (semaglutide) reduced body mass index (BMI) by at least 10% in nearly 80% of children with obesity aged 6 to under 12 years.

The phase 3 STEP Young trial found that 78.7% of children receiving semaglutide achieved this reduction after 68 weeks, compared with none in the placebo group.

However, the findings raise questions about the safety of GLP-1 medications in younger children. The World Health Organization (WHO) does not recommend weight-loss medicines for treating obesity in children under 10, citing limited evidence on their long-term safety and effectiveness.

What Did The STEP Young Trial Find?

Also read: Wegovy & Zepbound Are Not Approved By US FDA For Children Under 12: So Why Are Prescriptions Rising?

The phase 3 trial evaluated once-weekly semaglutide injections in children aged 6 to under 12 with obesity. Participants also followed a reduced-calorie diet and increased their physical activity.

The findings were presented at ObesityWeek 2026 and published in The New England Journal of Medicine.

After 68 weeks:

  • BMI decreased by 17.4% with semaglutide.
  • BMI increased by 2.2% with placebo.
  • 83% of children receiving semaglutide improved their BMI category, compared with 23.5% receiving placebo.
  • 40.4% were no longer classified as having obesity, compared with none in the placebo group, under the efficacy estimand.
More than 85% of participants had severe obesity at the start of the trial.

Why Do The Findings Matter?

Childhood obesity increases the risk of type 2 diabetes, high blood pressure, abnormal cholesterol levels and obstructive sleep apnea. Severe obesity can also affect a child's physical health, emotional well-being and daily life, with complications that may persist into adulthood.

The trial also found improvements in multiple cardiometabolic measures among children receiving semaglutide.

"Encouragingly, treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child's trajectory back towards one of improving weight-related health," said Ania M. Jastreboff, Professor of Medicine and Pediatrics at Yale School of Medicine and Director of the Yale Obesity Research Center.

What Are The Side Effects?

Read More: Are GLP-1 Drugs Safe for Children? Study Finds Nutritional Deficiency in Nearly 17% Within a Year

Adverse events were reported in 96% of children receiving semaglutide and 93% receiving placebo. Gastrointestinal problems were the most common and occurred more frequently among children taking the drug.

Common gastrointestinal side effects associated with semaglutide include nausea, vomiting, diarrhoea, constipation and abdominal pain.

Other potential risks associated with GLP-1 treatment include gallbladder problems, pancreatitis and dehydration.

WHO Advises Against Weight-Loss Drugs For Children Under 10

The WHO does not recommend weight-loss medicines, bariatric surgery or weight-management devices for children aged 0 to 9, as there is insufficient evidence on GLP-1 drugs in younger populations.

Instead, it recommends healthy eating, physical activity and behavioural support for children and their caregivers.

For adolescents aged 10 to 19, approved obesity medicines may be considered alongside structured lifestyle interventions.

Risks Of GLP-1 Use in Children

Read More: Childhood Obesity In India To Surge To 56 Million By 2040, Says Global Report

Despite these recommendations, GLP-1 prescriptions among younger children in the US are rising.

A NYU Langone Health study analysing health records of more than 3.5 million children found that prescriptions among those aged 8 to 11 with obesity increased more than 300-fold between 2019 and June 2026.

The GLP-1 medications approved for adolescents by the US FDA are not necessarily approved for children under 12.

However, a study from Northwestern University and Ann & Robert H. Lurie Children's Hospital of Chicago flagged nutritional deficiencies among young children taking GLP-drugs.

It showed that 16.8% of children aged 10 to 17 receiving GLP-1 medications developed a nutritional deficiency within a year. Vitamin D deficiency was the most common, affecting 12.4% of patients.

Amid limited long-term safety data, experts are concerned about prescribing appetite-suppressing drugs to children who are still growing, particularly because reduced appetite could lead to inadequate calorie and nutrient intake.

End of Article

Malaria Cases, Deaths Fall Nearly 80% In India, But Climate Change Could Pose New Threat: President Murmu

Updated Nov 17, 2026 | 09:32 PM IST

SummaryThe President warned that climate change, unplanned urbanization and insecticide resistance could hinder malaria elimination. She also flagged rising temperatures and shifting monsoon patterns as growing challenges for dengue.
Malaria Cases, Deaths Fall Nearly 80% In India, But Climate Change Could Pose New Threat: President Murmu

Credit: Health Ministry/X

Malaria cases and deaths in India declined by nearly 80% between 2015 and 2025, President Droupadi Murmu said on Tuesday, while warning that climate change, unplanned urbanization and growing mosquito resistance could create new challenges for malaria elimination.

Speaking at the inauguration of the Golden Jubilee celebrations of the Indian Council of Medical Research–National Institute of Malaria Research (ICMR–NIMR), the President called for sustained vigilance, stronger surveillance and greater community participation to achieve malaria elimination.

India Makes Progress In Malaria Control

The President noted that malaria remains a serious public health challenge in several countries, including India.

Recalling the situation at the time of independence, she said the vector-borne disease was among the country's most critical public health challenges. She also shared her personal observations of how malaria affected people's lives.

"During the monsoon season, fever was often accepted as an inevitable hardship of life. Children were unable to attend school, while farmers and laborers were often left unable to work for days on end. For the people, malaria was not merely a health issue—it was deeply intertwined with their livelihoods, education, and future," she said.

India has since made significant progress through sustained public health interventions. Between 2015 and 2025, malaria cases and deaths declined by nearly 80%, while the number of high-burden districts fell from 155 to 33.

As many as 160 districts reported zero indigenous malaria cases between 2022 and 2025, reflecting progress in interrupting local transmission and implementing targeted malaria control and elimination measures.

Calling the progress "remarkable", the President credited improved healthcare services, modern diagnostic techniques, effective medicines, mosquito-control campaigns and community participation for curbing the disease.

Also read: El Niño Could Worsen Dengue, Malaria And Heat Illness: Why WHO Declared A Health Emergency

Stronger Surveillance Needed To Eliminate Malaria

Despite the progress, malaria remains a challenge in certain regions, the President said, stressing the need for "sustained vigilance and effective efforts" to eliminate the disease.

She highlighted the importance of robust systems for malaria testing, treatment, surveillance and mosquito control.

Research aimed at developing new drugs and vaccines, along with public awareness and community participation, will also be vital for malaria elimination, she said.

Climate Change Could Pose New Challenges

The President warned that climate change, unplanned urbanization and growing mosquito resistance to insecticides could create new obstacles to malaria elimination efforts.

She also urged citizens to contribute to prevention efforts by avoiding water stagnation, eliminating mosquito breeding sites and maintaining a clean environment.

Beyond malaria, she noted that rising global temperatures and shifting monsoon patterns are further intensifying the challenge posed by dengue.

India Aims To Eliminate Malaria By 2030: Health Minister

Read More: Will India Be Malaria-Free By 2030? 160 Districts Report Zero Cases Over 3 Years; Burden Falls 80% In A Decade

Addressing the gathering, Union Minister of Health and Family Welfare Jagat Prakash Nadda said India's progress in malaria control over the past decade was the result of a comprehensive approach involving research on mosquito behaviour and malaria parasites, community participation, effective prevention, early diagnosis and appropriate treatment.

Highlighting India's progress in malaria control, Nadda noted that the country, which accounts for approximately 16% of the global population, contributes around 0.7% of global malaria cases and 0.6% of malaria deaths.

The Union Minister also appreciated India's exit from the WHO's High Burden to High Impact initiative and expressed confidence in achieving malaria elimination by 2030.

"We will eliminate malaria by 2030 by bringing about the necessary changes in our strategies and policies," he said, calling upon ICMR–NIMR to work with renewed commitment.

The Minister also highlighted ICMR's contributions to medical innovation, including MedTech Mitra, Patent Mitra and ELISA-based molecular diagnostics for dengue, chikungunya, Japanese encephalitis and other infectious diseases.

End of Article